IL144029A0 - Soluble receptor br43x2 and methods of using - Google Patents
Soluble receptor br43x2 and methods of usingInfo
- Publication number
- IL144029A0 IL144029A0 IL14402900A IL14402900A IL144029A0 IL 144029 A0 IL144029 A0 IL 144029A0 IL 14402900 A IL14402900 A IL 14402900A IL 14402900 A IL14402900 A IL 14402900A IL 144029 A0 IL144029 A0 IL 144029A0
- Authority
- IL
- Israel
- Prior art keywords
- seq
- amino acid
- acid residues
- antibody
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22653399A | 1999-01-07 | 1999-01-07 | |
PCT/US2000/000396 WO2000040716A2 (en) | 1999-01-07 | 2000-01-07 | Soluble receptor br43x2 and methods of using them for therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
IL144029A0 true IL144029A0 (en) | 2002-04-21 |
Family
ID=22849300
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14402900A IL144029A0 (en) | 1999-01-07 | 2000-01-07 | Soluble receptor br43x2 and methods of using |
IL144029A IL144029A (en) | 1999-01-07 | 2001-06-27 | 2X43BR soluble receptor and methods of use |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL144029A IL144029A (en) | 1999-01-07 | 2001-06-27 | 2X43BR soluble receptor and methods of use |
Country Status (29)
Country | Link |
---|---|
EP (5) | EP1642973B1 (de) |
JP (2) | JP5021117B2 (de) |
KR (1) | KR100699524B1 (de) |
CN (2) | CN1342202A (de) |
AT (3) | ATE437227T1 (de) |
AU (1) | AU780805B2 (de) |
BG (1) | BG65603B1 (de) |
BR (1) | BR0007423A (de) |
CA (2) | CA2753331A1 (de) |
CY (1) | CY1109977T1 (de) |
CZ (1) | CZ303272B6 (de) |
DE (3) | DE60043626D1 (de) |
DK (3) | DK1642972T3 (de) |
EA (1) | EA007471B1 (de) |
EE (2) | EE05539B1 (de) |
ES (3) | ES2329254T3 (de) |
HK (1) | HK1041497B (de) |
HU (1) | HU230024B1 (de) |
IL (2) | IL144029A0 (de) |
NO (2) | NO331902B1 (de) |
NZ (1) | NZ512753A (de) |
PL (3) | PL209535B1 (de) |
PT (2) | PT1141274E (de) |
SI (1) | SI1642972T1 (de) |
SK (1) | SK288176B6 (de) |
TR (1) | TR200101998T2 (de) |
UA (1) | UA74330C2 (de) |
WO (1) | WO2000040716A2 (de) |
ZA (1) | ZA200105288B (de) |
Families Citing this family (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8212004B2 (en) | 1999-03-02 | 2012-07-03 | Human Genome Sciences, Inc. | Neutrokine-alpha fusion proteins |
US6812327B1 (en) | 1996-10-25 | 2004-11-02 | Human Genome Sciences, Inc. | Neutrokine-alpha polypeptides |
US6689579B1 (en) | 1996-10-25 | 2004-02-10 | Human Genome Sciences, Inc. | Polynucleotides encoding neutrokine-α |
US6503184B1 (en) | 1997-10-21 | 2003-01-07 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2 |
US6689607B2 (en) | 1997-10-21 | 2004-02-10 | Human Genome Sciences, Inc. | Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2 |
US7488590B2 (en) | 1998-10-23 | 2009-02-10 | Amgen Inc. | Modified peptides as therapeutic agents |
ES2329254T3 (es) * | 1999-01-07 | 2009-11-24 | Zymogenetics, Inc. | Usos terapeuticos de receptores solubles de br43x2. |
US7833529B1 (en) | 1999-01-07 | 2010-11-16 | Zymogenetics, Inc. | Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor |
AU762839B2 (en) | 1999-01-25 | 2003-07-03 | Apoxis Sa | Baff, related blocking agents and their use in the stimulation and inhibition of B-cells and immunoglobulins in immune responses |
US20030095967A1 (en) | 1999-01-25 | 2003-05-22 | Mackay Fabienne | BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders |
US20030022233A1 (en) * | 1999-04-30 | 2003-01-30 | Raymond G. Goodwin | Methods of use of the taci/taci-l interaction |
AU4986700A (en) | 1999-05-06 | 2000-11-21 | National Jewish Medical And Research Center | Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof |
HU230583B1 (hu) * | 1999-08-17 | 2017-02-28 | Biogen Idec Ma Inc. | BAFF-receptor (BCMA) alkalmazásai immunszabályozó szerként |
UA74798C2 (uk) * | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
AU3695801A (en) * | 2000-02-11 | 2001-11-20 | Amgen, Inc. | Receptor from tnf family |
US20040002068A1 (en) * | 2000-03-01 | 2004-01-01 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
US6969519B2 (en) | 2000-03-10 | 2005-11-29 | Human Genome Sciences, Inc. | Methods of using an agonistic antibody human tumor necrosis factor receptor (TR17) |
DE60122337T2 (de) * | 2000-04-27 | 2007-08-16 | Biogen Idec Ma Inc., Cambridge | Verwendung von taci als antitumormittel |
EP1746106A3 (de) * | 2000-04-27 | 2007-03-14 | Biogen Idec MA Inc. | Verwendung von TACI als Antitumormittel |
US7371388B1 (en) | 2000-05-04 | 2008-05-13 | Human Genome Sciences, Inc. | Treatment of Sjogren's syndrome by administration of TR18 polypeptides |
JP2003533218A (ja) * | 2000-05-12 | 2003-11-11 | アムジエン・インコーポレーテツド | April/g70、bcma、blys/agp−3及びtaciに関する物質の組成物及び使用方法 |
US7879328B2 (en) | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
US7220840B2 (en) | 2000-06-16 | 2007-05-22 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator protein |
PT2275449T (pt) | 2000-06-16 | 2016-12-27 | Human Genome Sciences Inc | Anticorpos que se ligam imunoespecificamente a blys |
CA2418006A1 (en) * | 2000-08-18 | 2002-02-28 | Dyax Corp. | Binding polypeptides for b lymphocyte stimulator protein (blys) |
US20030091565A1 (en) | 2000-08-18 | 2003-05-15 | Beltzer James P. | Binding polypeptides and methods based thereon |
UA83458C2 (uk) | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf) |
WO2002046231A2 (en) * | 2000-12-07 | 2002-06-13 | The University Of British Columbia | Caml-binding peptides |
CA2438682A1 (en) * | 2001-02-20 | 2002-08-29 | Zymogenetics, Inc. | Antibodies that bind both bcma and taci |
NZ529267A (en) | 2001-05-11 | 2006-05-26 | Amgen Inc | Peptides and related molecules that bind to tall-1 |
RS52228B (en) * | 2001-05-24 | 2012-10-31 | Zymogenetics, Inc. | TACI-IMUNOGLOBULINSKI PROTEIN FUNCTIONS |
WO2003014294A2 (en) * | 2001-08-03 | 2003-02-20 | Genentech, Inc. | Tacis and br3 polypeptides and uses thereof |
WO2003013582A1 (en) * | 2001-08-06 | 2003-02-20 | Genset S.A. | Genoxit agonists and antagonists for use in the treatment of metabolic disorders |
US20060089311A1 (en) * | 2001-11-28 | 2006-04-27 | Deno Dialvnas | Agonists and antagonists of ryzn for the treatment of metabolic disorders |
CA2520097C (en) | 2003-03-28 | 2014-10-07 | Biogen Idec Ma Inc. | Truncated baff receptors |
EP1629001A2 (de) | 2003-06-05 | 2006-03-01 | Genentech, Inc. | Blys-antagonisten und deren verwendung |
WO2005075511A1 (en) | 2004-01-29 | 2005-08-18 | Genentech, Inc. | Variants of the extracellular domain of bcma and uses thereof |
AU2005257064B2 (en) * | 2004-06-28 | 2012-05-10 | Yeda Research And Development Co. Ltd. | Chimeric proteins and uses thereof |
EP1836224A1 (de) | 2004-12-23 | 2007-09-26 | Laboratoires Serono S.A. | Bcma polypeptide und deren verwendung |
ZA200801354B (en) | 2005-08-09 | 2009-08-26 | Ares Trading Sa | Methods for treating B-cell malignancies using TACI-lg fusion molecule |
JP5118037B2 (ja) * | 2005-08-09 | 2013-01-16 | ザイモジェネティクス, インコーポレイテッド | Taci融合分子を用いた異常細胞増殖の処置及び予防のための方法 |
US9168286B2 (en) | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
NZ568204A (en) * | 2005-10-13 | 2012-01-12 | Human Genome Sciences Inc | Methods and compositions for use in treatment of patients with autoantibody positive diseases |
MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
US9726673B2 (en) | 2005-11-23 | 2017-08-08 | Genentech, Inc. | Methods and compositions related to B cell assays |
US8211649B2 (en) | 2006-03-31 | 2012-07-03 | Human Genome Sciences, Inc. | Methods of diagnosing and prognosing hodgkin's lymphoma |
NZ572373A (en) | 2006-05-15 | 2012-02-24 | Ares Trading Sa | Methods for treating rheumatoid arthritis using a taci-ig fusion molecule |
EA017152B1 (ru) | 2006-08-28 | 2012-10-30 | Арес Трейдинг С.А. | СПОСОБ ОЧИСТКИ Fc-СОДЕРЖАЩИХ БЕЛКОВ |
AU2008208837A1 (en) | 2007-01-26 | 2008-07-31 | Merck Serono S.A. | Purification of Fc-TACT fusion proteins using the oilbody technology |
JP2011500715A (ja) | 2007-10-16 | 2011-01-06 | ザイモジェネティクス, インコーポレイテッド | 自己免疫疾患の治療のためのBLyS阻害剤および抗CD20剤の組合せ |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
PT2406284T (pt) | 2009-03-10 | 2016-09-29 | Biogen Ma Inc | Anticorpos anti-bcma |
KR20120104517A (ko) | 2009-09-03 | 2012-09-21 | 제넨테크, 인크. | 류마티스 관절염의 치료, 진단 및 모니터링 방법 |
WO2011109280A1 (en) | 2010-03-05 | 2011-09-09 | Lerner Research Institute | Methods and compositions to treat immune-mediated disorders |
EP2640750A1 (de) | 2010-11-16 | 2013-09-25 | Boehringer Ingelheim International GmbH | Mittel und verfahren zur behandlung von mit bcma-expression korrelierenden erkrankungen |
KR20140022815A (ko) | 2011-02-28 | 2014-02-25 | 제넨테크, 인크. | B-세포 길항제에 대한 반응을 예측하기 위한 생물학적 마커 및 방법 |
UA112434C2 (uk) | 2011-05-27 | 2016-09-12 | Ґлаксо Ґруп Лімітед | Антигензв'язувальний білок, який специфічно зв'язується з всма |
TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對bcma之e3以及cd3的結合分子 |
TW201334789A (zh) | 2012-01-31 | 2013-09-01 | Genentech Inc | 抗ige抗體及其使用方法 |
TW201425336A (zh) * | 2012-12-07 | 2014-07-01 | Amgen Inc | Bcma抗原結合蛋白質 |
US9963513B2 (en) | 2013-02-05 | 2018-05-08 | Engmab Sàrl | Method for the selection of antibodies against BCMA |
US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
JOP20140087B1 (ar) | 2013-03-13 | 2021-08-17 | Amgen Inc | بروتينات مخصصة ل baff و b7rp1 وإستخداماتها |
SI3126383T1 (sl) | 2014-04-03 | 2019-05-31 | Igm Biosciences, Inc. | Modificirana veriga J |
PL3247728T3 (pl) | 2015-01-20 | 2020-11-16 | Igm Biosciences, Inc. | Cząsteczki wiążące receptor nadrodziny czynnika martwicy nowotworów (TNF) i ich stosowanie |
DK3356401T3 (da) | 2015-09-30 | 2020-09-07 | Igm Biosciences Inc | Bindingsmolekyler med modificeret j-kæde |
EP3355913A1 (de) | 2015-09-30 | 2018-08-08 | IGM Biosciences A/S | Bindungsmoleküle mit modifizierter j-kette |
US11613572B2 (en) | 2016-06-21 | 2023-03-28 | Teneobio, Inc. | CD3 binding antibodies |
BR122022002481A8 (pt) | 2016-09-14 | 2023-02-07 | Teneobio Inc | Anticorpos biespecíficos de ligação específica para cd3delta-epsilon |
WO2018083204A1 (en) | 2016-11-02 | 2018-05-11 | Engmab Sàrl | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma |
JP7254699B2 (ja) | 2016-12-21 | 2023-04-10 | テネオバイオ, インコーポレイテッド | 抗bcma重鎖のみ抗体 |
EP3596100A4 (de) * | 2017-03-15 | 2021-01-13 | Juneau Biosciences, L.L.C. | Verfahren zur verwendung von mit endometriose assoziierten genetischen markern |
AU2018289515A1 (en) | 2017-06-20 | 2020-02-06 | Teneobio, Inc. | Anti-BCMA heavy chain-only antibodies |
WO2019229701A2 (en) | 2018-06-01 | 2019-12-05 | Novartis Ag | Binding molecules against bcma and uses thereof |
CN111944047B (zh) * | 2019-05-15 | 2022-04-08 | 重庆精准生物技术有限公司 | 抗bcma的人源化单链抗体及应用 |
JOP20210323A1 (ar) | 2019-06-14 | 2023-01-30 | Teneobio Inc | ارتباط أجسام مضادة ثقيلة السلسلة ومتعددة النوعية بـ cd22 وcd3 |
CR20230149A (es) | 2020-04-29 | 2023-05-25 | Teneobio Inc | Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas (divisional exp no 2022-539) |
CN116903727A (zh) | 2020-05-08 | 2023-10-20 | 高山免疫科学股份有限公司 | 具有和不具有t细胞抑制蛋白的april和baff抑制性免疫调节蛋白及其使用方法 |
WO2022047316A1 (en) | 2020-08-28 | 2022-03-03 | Sana Biotechnology, Inc. | Modified anti-viral binding agents |
KR20240019124A (ko) | 2021-05-07 | 2024-02-14 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Taci-fc 융합 면역조절 단백질의 투여 및 치료 방법 |
WO2024077018A2 (en) | 2022-10-04 | 2024-04-11 | Alpine Immune Sciences, Inc. | Methods and uses of taci-fc fusion immunomodulatory protein |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
AU560472B2 (en) | 1981-08-25 | 1987-04-09 | Celltech Limited | Yeast expression vectors |
US4579821A (en) | 1981-11-23 | 1986-04-01 | University Patents, Inc. | Control of DNA sequence transcription |
US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
US4486533A (en) | 1982-09-02 | 1984-12-04 | St. Louis University | Filamentous fungi functional replicating extrachromosomal element |
US4599311A (en) | 1982-08-13 | 1986-07-08 | Kawasaki Glenn H | Glycolytic promotersfor regulated protein expression: protease inhibitor |
US4977092A (en) | 1985-06-26 | 1990-12-11 | Amgen | Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
US5139936A (en) | 1983-02-28 | 1992-08-18 | Collaborative Research, Inc. | Use of the GAL1 yeast promoter |
US4661454A (en) | 1983-02-28 | 1987-04-28 | Collaborative Research, Inc. | GAL1 yeast promoter linked to non galactokinase gene |
US4870008A (en) | 1983-08-12 | 1989-09-26 | Chiron Corporation | Secretory expression in eukaryotes |
US4931373A (en) | 1984-05-25 | 1990-06-05 | Zymogenetics, Inc. | Stable DNA constructs for expression of α-1 antitrypsin |
US4766073A (en) | 1985-02-25 | 1988-08-23 | Zymogenetics Inc. | Expression of biologically active PDGF analogs in eucaryotic cells |
CA1280080C (en) | 1984-12-06 | 1991-02-12 | Jacques Oberto | Promoters for the expression of foreign genes in yeast, plasmids comprising them, and uses thereof for the production of polypeptides |
GR860984B (en) | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
US4882279A (en) | 1985-10-25 | 1989-11-21 | Phillips Petroleum Company | Site selective genomic modification of yeast of the genus pichia |
US4935349A (en) | 1986-01-17 | 1990-06-19 | Zymogenetics, Inc. | Expression of higher eucaryotic genes in aspergillus |
GB8611832D0 (en) | 1986-05-15 | 1986-06-25 | Holland I B | Polypeptide |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5063154A (en) | 1987-06-24 | 1991-11-05 | Whitehead Institute For Biomedical Research | Pheromone - inducible yeast promoter |
US5637677A (en) | 1987-07-16 | 1997-06-10 | The Trustees Of The University Of Pennsylvania | Biologically active compounds and methods of constructing and using the same |
EP0721983A1 (de) | 1988-01-22 | 1996-07-17 | ZymoGenetics, Inc. | Verfahren zur herstellung von biologisch-aktive Dimerpeptiden |
US5567584A (en) | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
US4956288A (en) | 1988-04-22 | 1990-09-11 | Biogen, Inc. | Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA |
US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5162228A (en) | 1988-12-28 | 1992-11-10 | Takeda Chemical Industries, Ltd. | Gylceraldehyde-3-phosphate dehydrogenase gene and promoter |
US5162222A (en) | 1989-07-07 | 1992-11-10 | Guarino Linda A | Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses |
EP0438803B1 (de) | 1990-01-26 | 1997-03-12 | Immunomedics, Inc. | Impfstoffe gegen Krebs und Infektionskrankheiten |
IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
US5208146A (en) | 1990-11-05 | 1993-05-04 | The Regents Of The University Of California | Murine monoclonal anti-idiotype antibodies |
EP1262560A2 (de) | 1992-05-29 | 2002-12-04 | Abbott Laboratories | Methode zur Herstellung von cDNA ausgehend von einer RNA Zielsequenz in einer Probe |
AU5103293A (en) | 1992-09-14 | 1994-04-12 | Oklahoma State University | Immortalized cells and uses therefor |
US6117679A (en) | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US5965389A (en) | 1995-11-09 | 1999-10-12 | Zymogenetics, Inc. | Production of GAD65 in methylotrophic yeast |
US5716808A (en) | 1995-11-09 | 1998-02-10 | Zymogenetics, Inc. | Genetic engineering of pichia methanolica |
WO1998002565A1 (en) | 1996-07-17 | 1998-01-22 | Zymogenetics, Inc. | TRANSFORMATION OF $i(PICHIA METHANOLICA) |
US5736383A (en) | 1996-08-26 | 1998-04-07 | Zymogenetics, Inc. | Preparation of Pichia methanolica auxotrophic mutants |
CA2261020C (en) | 1996-07-17 | 2004-06-08 | Zymogenetics, Inc. | Preparation of pichia methanolica auxotrophic mutants |
BR9612752A (pt) * | 1996-10-25 | 2000-01-18 | Human Genome Sciences Inc | Neutrocina |
US5969102A (en) * | 1997-03-03 | 1999-10-19 | St. Jude Children's Research Hospital | Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof |
CA2232743A1 (en) * | 1997-04-02 | 1998-10-02 | Smithkline Beecham Corporation | A tnf homologue, tl5 |
EP1012292A1 (de) * | 1997-06-06 | 2000-06-28 | Regeneron Pharmaceuticals, Inc. | Ntn-2, mitglied von tnf-ligand-familie |
AU7608898A (en) * | 1997-06-06 | 1998-12-21 | Regeneron Pharmaceuticals, Inc. | Ntn-2 member of tnf ligand family |
ES2329254T3 (es) * | 1999-01-07 | 2009-11-24 | Zymogenetics, Inc. | Usos terapeuticos de receptores solubles de br43x2. |
-
2000
- 2000-01-07 ES ES05018985T patent/ES2329254T3/es not_active Expired - Lifetime
- 2000-01-07 PL PL364817A patent/PL209535B1/pl unknown
- 2000-01-07 NZ NZ512753A patent/NZ512753A/en not_active IP Right Cessation
- 2000-01-07 AT AT05018985T patent/ATE437227T1/de active
- 2000-01-07 CZ CZ20012465A patent/CZ303272B6/cs not_active IP Right Cessation
- 2000-01-07 EP EP05018985A patent/EP1642973B1/de not_active Expired - Lifetime
- 2000-01-07 AT AT00902354T patent/ATE249517T1/de active
- 2000-01-07 KR KR1020017008642A patent/KR100699524B1/ko active IP Right Grant
- 2000-01-07 EA EA200100621A patent/EA007471B1/ru not_active IP Right Cessation
- 2000-01-07 EP EP10175468A patent/EP2256199A1/de not_active Withdrawn
- 2000-01-07 PT PT00902354T patent/PT1141274E/pt unknown
- 2000-01-07 DE DE60043626T patent/DE60043626D1/de not_active Expired - Lifetime
- 2000-01-07 SI SI200031056T patent/SI1642972T1/sl unknown
- 2000-01-07 EP EP05018984A patent/EP1642972B1/de not_active Expired - Lifetime
- 2000-01-07 ES ES05018984T patent/ES2338661T3/es not_active Expired - Lifetime
- 2000-01-07 PT PT05018984T patent/PT1642972E/pt unknown
- 2000-01-07 AT AT05018984T patent/ATE453712T1/de active
- 2000-01-07 EP EP00902354.0A patent/EP1141274B2/de not_active Expired - Lifetime
- 2000-01-07 HU HU0200429A patent/HU230024B1/hu not_active IP Right Cessation
- 2000-01-07 SK SK971-2001A patent/SK288176B6/sk not_active IP Right Cessation
- 2000-01-07 DE DE60005135.8T patent/DE60005135T3/de not_active Expired - Lifetime
- 2000-01-07 DK DK05018984.4T patent/DK1642972T3/da active
- 2000-01-07 EP EP03016020A patent/EP1354598A3/de not_active Withdrawn
- 2000-01-07 DK DK05018985T patent/DK1642973T3/da active
- 2000-01-07 BR BR0007423-3A patent/BR0007423A/pt active Search and Examination
- 2000-01-07 JP JP2000592413A patent/JP5021117B2/ja not_active Expired - Lifetime
- 2000-01-07 CN CN00804425A patent/CN1342202A/zh active Pending
- 2000-01-07 DE DE60042617T patent/DE60042617D1/de not_active Expired - Lifetime
- 2000-01-07 CA CA2753331A patent/CA2753331A1/en not_active Abandoned
- 2000-01-07 ES ES00902354.0T patent/ES2204502T5/es not_active Expired - Lifetime
- 2000-01-07 IL IL14402900A patent/IL144029A0/xx unknown
- 2000-01-07 CA CA2358520A patent/CA2358520C/en not_active Expired - Fee Related
- 2000-01-07 PL PL385677A patent/PL211033B1/pl unknown
- 2000-01-07 PL PL393286A patent/PL393286A1/pl not_active Application Discontinuation
- 2000-01-07 WO PCT/US2000/000396 patent/WO2000040716A2/en active Search and Examination
- 2000-01-07 EE EEP201100048A patent/EE05539B1/xx not_active IP Right Cessation
- 2000-01-07 TR TR2001/01998T patent/TR200101998T2/xx unknown
- 2000-01-07 CN CNA2008101667017A patent/CN101518648A/zh active Pending
- 2000-01-07 AU AU24084/00A patent/AU780805B2/en not_active Expired
- 2000-01-07 EE EEP200100360A patent/EE05460B1/xx not_active IP Right Cessation
- 2000-01-07 DK DK00902354.0T patent/DK1141274T4/en active
- 2000-07-01 UA UA2001074748A patent/UA74330C2/uk unknown
-
2001
- 2001-06-27 IL IL144029A patent/IL144029A/en not_active IP Right Cessation
- 2001-06-27 ZA ZA2001/05288A patent/ZA200105288B/en unknown
- 2001-07-04 NO NO20013316A patent/NO331902B1/no not_active IP Right Cessation
- 2001-07-05 BG BG105674A patent/BG65603B1/bg unknown
-
2002
- 2002-02-09 HK HK02101043.3A patent/HK1041497B/zh not_active IP Right Cessation
-
2010
- 2010-03-30 CY CY20101100298T patent/CY1109977T1/el unknown
-
2011
- 2011-08-09 JP JP2011173965A patent/JP2012001550A/ja active Pending
- 2011-11-21 NO NO20111595A patent/NO333915B1/no not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL144029A0 (en) | Soluble receptor br43x2 and methods of using | |
AU5510286A (en) | Polypeptides complementary to peptides or proteins having an amino acid sequence or nucleotide coding sequence at least partially known and methods of design therefor | |
Kwong et al. | Identification of succinimide sites in proteins by N‐terminal sequence analysis after alkaline hydroxylamine cleavage | |
CA2093927A1 (en) | Ligand-mediated immunofunctional hormone binding protein assay method | |
Benoit et al. | Peptides: strategies for antibody production and radioimmunoassays | |
Müllner et al. | A radioimmunoassay for the determination of insulins from several animal species, insulin derivatives and insulin precursors in both their native and denatured state | |
NO942539D0 (no) | Caseinmakropeptid, antistoffer rettet mot nevnte peptider og anvendelser derav | |
AR018045A1 (es) | Proteina placentaria 13 y polipetido, molecula de adn que los codifica, anticuerpos capaces de enlazarse a ellos, metodo para la deteccion decomplicaciones relacionadas con el embarazo, metodo recombinante para la produccion de dicha proteina y un equipo para el diagnostico de complicacionesrelacion | |
Furka et al. | An improved method for isolation of the C-terminal fragment of proteins | |
GR3026434T3 (en) | An antibody to the carboxyl terminus peptide of rat somatotropin binding protein | |
JP2007526919A5 (de) | ||
Benhamini et al. | Immunochemical studies with synthetic peptides related to collagen |